UK approves GSK's Covid antibody drug that slashes risk of death and hospitalisation

Sotrovimab, sold under the brand name Xevudy, cuts the risk of hospitalisation by 79 per cent among those at risk from the virus. But there are fears it may be less effective against Omicron.

from Health News | Mail Online https://ift.tt/31iDxbb